Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 12, 2022 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Fox Chase Cancer Center
- Interventions being studied
- Drug: bevacizumab; Drug: Erlotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy.
- ECOG PS 0-1
- 70 years of age or older
- Must have measurable disease
- ANC \> 1500, platelets \> 100,000
- Total bilirubin \</= 1.5, SGOT \
- SGPT \< 5 x ULN
- Able and willing to swallow and absorb oral medication
- Able and willing to sign consent
- Request archival diagnostic tissue for EGFR expression but not required
- Proteinuria as demonstrated by UPC ratio \>/= 1.0
- Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide)
- Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic)
- History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation
- Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment.
- Current, ongoing treatment with full dose warfarin or equivalent
- Current(within 10 days)use of aspirin (\> 325mg/day) or other NSAID with antiplatelet activity
- History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD
- Known CNS disease except for treated brain mets.
- Squamous cell histology
- Blood pressure \> 150/100 that cannot be ameliorated with standard anti-hypertensives
- History of hypertensive crisis or hypertensive encephalopathy
- NYHA grade II or \> CHF
- History of MI within 6 months of enrollment
- Major surgery, open biopsy, significant trauma within 28 days of enrollment
- Pregnancy, lactation
- Abdominal or other fistula, abcess, perforation
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- AtlantiCare Regional Medical CenterGalloway, New Jersey
- Fox Chase Virtua Health Cancer Program at MemorialMount Holly, New Jersey
- Paoli HospitalPaoli, Pennsylvania
- Abramson Cnacer Center, University of PennsylvaniaPhiladelphia, Pennsylvania
- Pennsylvania Oncology Hematology AssociatesPhiladelphia, Pennsylvania
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
- Grand View HospitalSellersville, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 12, 2022. Always confirm current availability with the study team.